Jonathan Pollock

USPTO Granted Patents = 10 (Patent Applications = 3)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 9.5

ph-index = 5

Forward Citations = 59(Granted Patents)

Company Filing History:

University of Michigan

patents

where one patent can have more than one assignee

Years Active: 2018-2023

Loading Chart...

10 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. RE49687 - Thienopyrimidine and thienopyridine compounds and methods of use thereof (2023-10-10),

2. 11673898 - Substituted inhibitors of menin-MLL and methods of use (2023-06-13),

3. 11555041 - Bridged bicyclic inhibitors of menin-MLL and methods of use (2023-01-17),

4. 11542248 - Methods and compositions for inhibiting the interaction of menin with MLL proteins (2023-01-03),

5. 10781218 - Substituted inhibitors of menin-MLL and methods of use (2020-09-22),

6. 10752639 - Bridged bicyclic inhibitors of menin-MLL and methods of use (2020-08-25),

7. 10588907 - Methods and compositions for inhibiting the interaction of menin with MLL proteins (2020-03-17),

8. 10246464 - Thienopyrimidine and thienopyridine compounds and methods of use thereof (2019-04-02),

9. 10174041 - Methods and compositions for inhibiting the interaction of menin with MLL proteins (2019-01-08),

10. 10077271 - Methods and compositions for inhibiting the interaction of menin with MLL proteins (2018-09-18),

Title: Jonathan Pollock: Innovator in Cancer Treatment Solutions

Introduction

Jonathan Pollock is a prominent inventor based in Ann Arbor, MI, known for his significant contributions to the field of cancer therapeutics. With a portfolio of 10 patents, Pollock has dedicated his career to developing innovative compounds and methods aimed at combating various forms of cancer and other related diseases.

Latest Patents

Among his latest inventions, Pollock has introduced groundbreaking patents focusing on thienopyrimidine and thienopyridine compounds. These patents disclose novel compounds and methods designed to inhibit the interaction between menin and its associated signaling molecules, including MLL1, MLL2, and MLL-fusion oncoproteins. The implications of these inventions are vast, as they can be utilized in treating a wide array of cancers and diseases linked to MLL proteins and menin.

Additionally, Pollock's patent on substituted inhibitors of the menin-MLL interaction outlines methods to disrupt the binding of menin with MLL1, MLL2, and related oncoproteins. This formulation shows promise in the treatment of leukemia, solid tumors, diabetes, and other diseases reliant on the activity of MLL and menin.

Career Highlights

Pollock's career has been marked by notable achievements and contributions in the realms of biotechnology and pharmacology. His work with Kura Oncology, Inc. and the University of Michigan has allowed him to refine his research and translate innovative concepts into practical applications.

Collaborations

During his career, Pollock has collaborated with talented individuals such as Tao Wu and Liansheng Li. Their partnerships have facilitated the advancement of medical research and the generation of promising therapeutic solutions.

Conclusion

In conclusion, Jonathan Pollock stands out as a significant innovator in cancer treatment, with a strong foundation in research and development. His patents illustrate his commitment to enhancing medical science and improving patient outcomes in complex diseases. As he continues his work, the impact of his inventions is poised to benefit countless individuals facing challenging health conditions.

This text is generated by artificial intelligence and may not be accurate.